Neucomed GmbH, founded in 2016, specializes in developing and marketing innovative medical devices for the treatment of cardiac and neurological disorders. Our primary focus includes the diagnosis and treatment of epilepsy, heart failure, and structural heart diseases, impacting millions of patients worldwide.

In the DACH region, we assist global companies in accessing the European market. We support the CE marking process and act as a liaison with competent authorities and notified bodies. As an authorized representative and distributor, we leverage our extensive European distribution network and direct affiliates.

Additionally, Neucomed has a dedicated pharmaceutical division, enhancing our commitment to improving patient outcomes through advanced medical solutions.

Neucomed is part of the GENAERO Group. GENAERO, encompassing the brands TEST-FUCHS and NEUCOMED, is a privately-owned group with over 600 employees and offices in Austria, Germany, the UK, France, Italy, Spain, the USA, and Singapore. TEST-FUCHS is dedicated to designing and manufacturing testing systems, equipment, and components for the aerospace industry.

Neucomed GmbH                                      
Donau-City-Straße 7/26                          
Austria, 1220 Vienna

Neucomed Deutschland GmbH
Albert-Einstein-Straße 3
Germany, 85435 Erding

Neucomed Schweiz GmbH      
c/o BDO AG
Industriestrasse 53
Switzerland, 6312 Steinhausen

Neucomed

Org chart

Teams

Offices